Abstract：
Background: The standard therapeutic regimen for idiopathic chronic eosinophilic pneumonia (ICEP) involves the administration of oral corticosteroids (OCS). However, a notable proportion of individuals experience recurrent episodes after the tapering or cessation of OCS during the course of ICEP. There has been a growing interest in exploring alternative treatment modalities for patients with ICEP at heightened risk of relapse. Objective: The aim of this study was to assess the efficacy of mepolizumab at a dose of 100 mg administered every 4 weeks in preventing relapses of ICEP and its impact on the clinical outcomes. Methods: This retrospective clinical observational study used real-world data to assess the impact of mepolizumab on patients diagnosed with ICEP accompanied by severe asthma. Demographic information and clinical characteristics were extracted from medical records. The study examined the effect of mepolizumab on the annual relapse rate, OCS dose, eosinophil count, and respiratory function parameters. Results: All patients included in the study, with a median (range) follow-up period of 19 months (4-40 months), the annual relapse rate decreased from 0.33 to 0 after the initiation mepolizumab. In addition, the maintenance OCS dose, expressed in methylprednisolone equivalents, declined from 4 mg/day to 0 mg/day. A reduction in the blood eosinophil count was observed, alongside a partial improvement in respiratory function test results among the patients. Conclusıon: A dose regimen of 100 mg of mepolizumab administered every 4 weeks emerges as a promising and well-tolerated therapeutic approach for averting relapses of ICEP.
摘要：
背景：特发性慢性嗜酸性粒细胞肺炎（ICEP）的标准治疗方案包括口服皮质类固醇（OCS）。然而,相当比例的个体在ICEP过程中OCS逐渐减少或停止后经历反复发作。对于探索复发风险较高的ICEP患者的替代治疗方式，人们越来越感兴趣。目的：这项研究的目的是评估每4周100mg剂量的美泊利单抗预防ICEP复发的疗效及其对临床结果的影响。方法：这项回顾性临床观察研究使用真实世界的数据来评估美泊利单抗对诊断为ICEP并伴有严重哮喘的患者的影响。从病历中提取人口统计学信息和临床特征。该研究检查了美泊利单抗对年复发率的影响，OCS剂量,嗜酸性粒细胞计数,和呼吸功能参数。结果：纳入研究的所有患者，中位（范围）随访期为19个月（4-40个月），开始使用美泊利单抗后,年复发率从0.33降至0.此外,维持OCS剂量，以甲基强的松龙当量表达，从4毫克/天下降到0毫克/天。观察到血液嗜酸性粒细胞计数减少，患者的呼吸功能测试结果有所改善。结论：每4周给予100mg美泊利单抗的剂量方案成为避免ICEP复发的有希望且耐受性良好的治疗方法。
